Introduction: Opioid agonist treatment (OAT) is the most common and most effective treatment option for persons with opioid use disorders (OUD). In Germany, the prescription of OAT medications is regulated by the Narcotic Drugs Prescription Ordinance. With the introduction of restrictions to contain the SARS-CoV-2 virus, the German OAT regulations have been amended to ensure a legal continuation of OAT for people with OUD. In this study, we aimed to examine the use of the OAT regulations in practice, the experience made by physicians prescribing OAT medications, and their perspective on OAT regulations. Methods: Between September and December 2021, a questionnaire on the current situation and potential changes in the provision of OAT during the COVID-19 pandemic was sent out to 2,416 German physicians prescribing OAT medications. Differences between physicians with and without addiction medicine certification were analyzed. Results: The response rate of physicians was 22.8%. Their average age was 57.4 (±10.1) years, and 62.3% were male. During the COVID-19 pandemic, take-home periods for stable patients have been extended by 48.2% of physicians, and 52.6% would like to maintain this prescribing practice in the future. Most physicians (71.6%) indicated that patients handled the extended take-home prescriptions predominantly responsibly. A total of 71.8% of the physicians generally did not use video consultation. A corona pandemic-related switch of the OST medication to depot buprenorphine injection did rather not occur, as 71.2% reported no patients treated with depot buprenorphine, and only 2.6% switched first-time or more patients to depot buprenorphine due to the COVID-19 pandemic. Conclusion: The corona situation opened up opportunities for physicians and patients and enabled change processes in OAT. Physicians had positive experiences implementing expanded take-home prescriptions for stable patients. Video contacts rarely took place, suggesting resistance to digital consultation. The number of depot buprenorphine prescriptions has not increased substantially since the pandemic’s beginning and has remained at low levels. Further research is needed to assess to what extent the changes in OAT will be maintained over time and whether they will also lead to long-term benefits for OAT patients.

1.
World Health Organization (WHO)
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
.
2009
.
2.
Mattick
R
,
Breen
C
,
Kimber
J
,
Davoli
M
.
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
.
Cochrane Database Syst Rev
.
2009
2009
3
CD002209
.
3.
Degenhardt
L
,
Bucello
C
,
Mathers
B
,
Briegleb
C
,
Ali
H
,
Hickman
M
.
Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies
.
Addiction
.
2011
;
106
(
1
):
32
51
.
4.
Amato
L
,
Minozzi
S
,
Davoli
M
,
Vecchi
S
.
Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence Cochrane
.
Database Syst Rev
.
2011
10
CD004147
.
5.
Mongan
D
,
Galvin
B
,
Farragher
L
,
Dunne
M
,
Nelson
M
.
An evidence brief impact of COVID-19 on drug services in four countries
.
Health Res Board
.
2020
;
17
(
1
):
95
.
6.
Dunlop
A
,
Lokuge
B
,
Masters
D
,
Sequeira
M
,
Saul
P
,
Dunlop
G
.
Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
.
Harm Reduct J
.
2020
;
17
(
1
):
26
.
7.
Crowley
D
,
Cullen
W
.
Caring for opioid drug users during the COVID-19 pandemic: a commentary on the Irish experience
.
Health Res Board
.
2021
23
.
8.
Frank
D
.
A chance to do it better: methadone maintenance treatment in the age of Covid-19
.
J Subst Abuse Treat
.
2021
;
123
:
108246
.
9.
Hennigan
K
,
Corrigan
N
,
Killeen
N
,
Scully
M
,
Keenan
E
.
Response of tertiary addictions services to opioid dependence during the COVID-19 pandemic
.
Ir J Psychol Med
.
2021
;
38
(
4
):
301
6
.
10.
Leppla
I
,
Gross
M
.
Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2)
.
J Addict Med
.
2020
;
14
(
4
):
e1
3
.
11.
MacKinnon
L
,
Socías
E
,
Bardwell
G
.
COVID-19 and overdose prevention: challenges and opportunities for clinical practice in housing settings
.
J Subst Abuse Treat
.
2020
;
119
:
108153
.
12.
Straub
A
,
Pastor
A
,
Lloyd-Jones
M
,
O’Neill
H
,
Bonomo
Y
.
The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic
.
Drug Alcohol Rev
.
2021
;
40
(
4
):
681
2
.
13.
Sun
Y
,
Bao
Y
,
Kosten
T
,
Strang
J
,
Shi
J
,
Lu
L
.
Editorial: challenges to opioid use disorders during COVID-19
.
Am J Addict
.
2020
;
29
(
3
):
174
5
.
14.
Krawczyk
N
,
Fawole
A
,
Yang
J
,
Tofighi
B
.
Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review
.
Addict Sci Clin Pract
.
2021
;
16
(
1
):
68
.
15.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bundesopiumstelle
Bericht zum Substitutionsregister (Januar 2022)
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
2022
. Available from: https://www.bfarm.de/SharedDocs/Downloads/DE/Bundesopiumstelle/SubstitReg/Subst_Bericht2022.pdf;jsessionid=84B93B37A517F0B6B9D2437980E9580A.intranet671?__blob=publicationFile.
16.
Kraus
L
,
Seitz
N
,
Schulte
B
,
Cremer-Schaeffer
P
,
Braun
B
,
Verthein
U
.
Estimation of the number of people with opioid addiction in Germany
.
Dtsch Arztebl Int
.
2019
;
116
(
9
):
137
43
.
17.
Bundesärztekammer
(Muster-)Weiterbildungsordnung 2018
. In der Fassung vom 25.06.2022;
2018
.
18.
Bundesärztekammer
Muster- Kursbuch Suchtmedizinische Grundversorgung auf der Grundlage der (Muster-)Weiterbildungsordnung 2018
Berlin
2022
.
19.
Dritte Bundesanzeiger
Verordnung zur Änderung der Betäubungsmittel‐Verschreibungsverordnung vom 22 Mai 2017
.
2017
. Available from: https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl117s1275.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl117s1275.pdf%27%5D__1598600639518.
20.
Batra
A
,
Meyer-Thompson
H
Die Dritte Verordnung zur Änderung der Betäubungsmittel-Verschreibungsverordnung: was hat sich geändert?
Bundesministerium für Gesundheit
2017
;
63
(
4
):
227
8
.
21.
Bundesanzeiger. Bundesministerium für Gesundheit. Verordnung über Abweichungen von den Vorschriften des Fünften Buches Sozialgesetzbuch, des Apothekengesetzes, der Apothekenbetriebsordnung, der Arzneimittelpreisverordnung, des Betäubungsmittelgesetzes und der Betäubungsmittel-Verschreibungsverordnung infolge der SARS-CoV-2-Epidemie (SARS-CoV-2-Arzneimittelversorgungsverordnung): bundesministerium der Justiz und für Verbraucherschutz;
2020
. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Gesetze_und_Verordnungen/GuV/A/SARS-CoV-2-AMVersorgVO_Bgbl.PDF.
22.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bundesopiumstelle. Bericht zum Substitutionsregister (Januar 2023). Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
2023
. https://www.bfarm.de/SharedDocs/Downloads/DE/Bundesopiumstelle/SubstitReg/Subst_Bericht2023.pdf?__blob=publicationFile.
23.
Fenton
F
,
Stokes
S
,
Eagleton
M
.
A cross-section observational study on the seroprevalence of antibodies to COVID-19 in patients receiving opiate agonist treatment
.
Ir J Med Sci
.
2021
;
191
(
3
):
1053
8
.
24.
Bruggmann
P
,
Senn
O
,
Frei
A
,
Puhan
M
,
Fehr
J
,
Falcato
L
.
High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study
.
Swiss Med Wkly
.
2022
152
w30122
w30122
.
25.
Qeadan
F
,
Tingey
B
,
Bern
R
,
Porucznik
C
,
English
K
,
Saeed
A
.
Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the Cerner Real-World Data
.
EClinicalMedicine
.
2021
;
37
:
100938
.
26.
Figgatt
M
,
Salazar
Z
,
Day
E
,
Vincent
L
,
Dasgupta
N
.
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19
.
J Subst Abuse Treat
.
2021
;
123
:
108276
.
27.
Madden
E
,
Christian
B
,
Lagisetty
P
,
Ray
B
,
Sulzer
S
.
Treatment provider perceptions of take-home methadone regulation before and during COVID-19
.
Drug Alcohol Depend
.
2021
;
228
:
109100
.
28.
McDonald
R
,
Bech
AB
,
Clausen
T
Flexible delivery of opioid agonist treatment during COVID-19 in Norway: a cross-sectional survey of provider experiences
.
2023
.
29.
Lintzeris
N
,
Deacon
R
,
Hayes
V
,
Cowan
T
,
Mills
L
,
Parvaresh
L
.
Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia
.
Drug Alcohol Rev
.
2021
;
41
(
5
):
1009
19
.
30.
Russell
C
,
Ali
F
,
Nafeh
F
,
Rehm
J
,
LeBlanc
S
,
Elton-Marshall
T
.
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study
.
J Subst Abuse Treat
.
2021
;
129
:
108374
.
31.
Meyer
M
,
Strasser
J
,
Köck
P
,
Walter
M
,
Vogel
M
,
Dürsteler
K
.
Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic: is an update of legal restrictions warranted
.
Int J Drug Policy
.
2022
;
101
:
103548
.
32.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons: results from an EMCDDA trendspotter study
Luxembourg
2021
.
33.
Kassenärztliche Bundesvereinigung (KBV). Einheitliche Bewertungsmaßstab (EBM), Substitutionsgestützte Behandlung Opioidabhängiger (GOP 01950);
2023
. Available from: https://www.kbv.de/tools/ebm/html/01950_2900671796960197270848.html.
34.
Kassenärztliche Bundesvereinigung (KBV). Einheitliche Bewertungsmaßstab (EBM), Substitutionsgestützte Behandlung Opioidabhängiger im Rahmen der Take-Home-Vergabe (GOP 01949);
2023
. Available from: https://www.kbv.de/tools/ebm/html/01949_2901568063576794158880.html.
35.
ÄrzteZeitung
DAK
Gesundheit. 3.
Digitalisierungsreport. Digitale Gesundheitslösungen
Skepsis von Ärztinnen und Ärzten überwinden
.
2021
.
36.
Arunogiri
S
,
Lintzeris
N
.
Depot buprenorphine during COVID-19 in Australia: opportunities and challenges
.
J Subst Abuse Treat
.
2021
;
124
:
108221
.
37.
Deutsches
Ä
rzteblatt. Ländervergleich
.
Deutschland hinkt bei Digitalisierung in der Medizin hinterher
2021
. https://www.aerzteblatt.de/nachrichten/124045/Laendervergleich-Deutschland-hinkt-bei-Digitalisierung-in-der-Medizin-hinterher.
38.
Trujols
J
,
Larrabeiti
A
,
Sànchez
O
,
Madrid
M
,
De Andrés
S
,
Duran-Sindreu
S
.
Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care
.
J Subst Abuse Treat
.
2020
;
119
:
108154
.
39.
Substance Abuse and Mental Health Services Administration (SAMHSA)
SAMHSA extends the methadone take-home flexibility for one year while working toward a permanent solution
.
2021
. Available from: https://www.samhsa.gov/newsroom/press-announcements/202111181000.
40.
Schulte
B
,
Schmidt
C
,
Kuhnigk
O
,
Schäfer
I
,
Fischer
B
,
Wedemeyer
H
.
Structural barriers in the context of opiate substitution treatment in Germany-a survey among physicians in primary care
.
Subst Abuse Treat Prev Pol
.
2013
;
8
(
26
):
26
.
41.
Lehmann
K
,
Kuhn
S
,
Schulte
B
,
Meyer-Thompson
H-G
,
Verthein
U
.
[Opioid substitution treatment in Germany: physicians’ view on the effects of the 3rd revision of the narcotic drugs prescription ordinance]
.
Gesundheitswesen
.
2021
83
08/09
651
61
.
You do not currently have access to this content.